- Home
- BWB vs ERAS Comparison
BWB vs ERAS Comparison
Compare BWB & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWB
- ERAS
- Stock Information
- Founded
- BWB 2005
- ERAS 2018
- Country
- BWB United States
- ERAS United States
- Employees
- BWB N/A
- ERAS N/A
- Industry
- BWB Major Banks
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- BWB Finance
- ERAS Health Care
- Exchange
- BWB Nasdaq
- ERAS Nasdaq
- Market Cap
- BWB 442.3M
- ERAS 439.7M
- IPO Year
- BWB 2018
- ERAS 2021
- Fundamental
- Price
- BWB $16.46
- ERAS $2.42
- Analyst Decision
- BWB Strong Buy
- ERAS Buy
- Analyst Count
- BWB 2
- ERAS 6
- Target Price
- BWB $20.50
- ERAS $3.67
- AVG Volume (30 Days)
- BWB 134.9K
- ERAS 1.8M
- Earning Date
- BWB 10-21-2025
- ERAS 11-07-2025
- Dividend Yield
- BWB N/A
- ERAS N/A
- EPS Growth
- BWB 25.72
- ERAS N/A
- EPS
- BWB 1.32
- ERAS N/A
- Revenue
- BWB $127,243,000.00
- ERAS N/A
- Revenue This Year
- BWB $35.74
- ERAS N/A
- Revenue Next Year
- BWB $12.55
- ERAS N/A
- P/E Ratio
- BWB $12.47
- ERAS N/A
- Revenue Growth
- BWB 20.40
- ERAS N/A
- 52 Week Low
- BWB $11.93
- ERAS $1.01
- 52 Week High
- BWB $18.01
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- BWB 44.35
- ERAS 56.95
- Support Level
- BWB $16.30
- ERAS $2.34
- Resistance Level
- BWB $17.14
- ERAS $2.54
- Average True Range (ATR)
- BWB 0.68
- ERAS 0.15
- MACD
- BWB -0.11
- ERAS -0.02
- Stochastic Oscillator
- BWB 19.77
- ERAS 51.58
About BWB Bridgewater Bancshares Inc.
Bridgewater Bancshares Inc is a financial holding company. Through its subsidiary, it offers various personal and commercial banking products and services such as savings accounts, certificates of deposits, money transfer services, digital wallets, credit and debit cards, safe deposit lockers, different types of loans and advances, commercial deposit accounts, treasury management, and others. The company principally focuses on catering to commercial clients, offering them a suite of loan and deposit products. Geographically, it mainly operates in the Twin Cities Metropolitan Statistical Area in the United States.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.